Gene therapy has the potential to eliminate a number of diseases which are currently causing distress to patients and burden on the healthcare system. Gene therapies have been tested in vitro and were deployed in the clinic for the first time in 2017. The promise of a ‘cure’ has proved tempting for investors and developers alike.

In this editorial feature, we will be discussing current the landscape of gene therapy and existing applications. We will review the unique manufacturing requirements of gene therapies and how developers and vendors are supporting this process. Finally, we will hear from leading experts in the field, who will review ethical and regulatory developments that could impact developers and patients. 

Since 2006, the award-winning peer-reviewed journal Regenerative Medicine (IF:2.868, MEDLINE-indexed) has been at the forefront of publishing the best in clinical translation, commercialization and regulation. By delivering the latest original research, reviews and opinions from leaders in the field, Regenerative Medicine continues to provide a specialist forum addressing the important challenges and advances in this rapidly evolving sector.

Read the latest journal news here, plus, exclusively for RegMedNet members, get free access to selected papers. For more information on Regenerative Medicine and to check out all the latest content, visit the journal site.

This channel includes the latest news, interviews and opinion pieces on regenerative medicine, stem cells, cell and gene therapy, and other advanced therapies from around the world, aiming to keep you up to date with the field and aware of different insights and perspectives.

Watch these webinars and panel discussions to learn about the latest developments and technologies directly from experts within the field and to pose your own questions to the presenters.